Aeovian Pharmaceuticals, Inc. announced that it has raised $50 million in a round of funding led by new investor, Hevolution Foundation on March 28, 2024. The transaction included participation from returning investors, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG.
Market Closed -
Other stock markets
|
After market 03:23:06 pm | |||
9.625 EUR | +4.22% | 9.678 | +0.55% |
Apr. 26 | EVOTEC : Deutsche Bank gives a Buy rating | ZD |
Apr. 25 | The specter of stagflation rears its ugly head again |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-54.77% | 1.75B | |
+1.46% | 42.75B | |
+47.70% | 41.61B | |
+11.69% | 41.34B | |
-8.83% | 26.59B | |
+6.45% | 25.49B | |
-23.58% | 18.12B | |
+29.87% | 12.24B | |
-2.41% | 11.76B | |
+7.93% | 11B |
- Stock Market
- Equities
- EVT Stock
- News Evotec SE
- Aeovian Pharmaceuticals, Inc. announced that it has received $50 million in funding from Hevolution Foundation, Apollo Health Ventures, Sofinnova Investment, Inc., venBio LLC, Evotec SE, b2venture AG